Sang-Hyun Cho

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7624925/publications.pdf

Version: 2024-02-01

53 papers	2,605 citations	159358 30 h-index	189595 50 g-index
54 all docs	54 docs citations	54 times ranked	3241 citing authors

#	Article	IF	Citations
1	In VitroProfiling of Antitubercular Compounds by Rapid, Efficient, and Nondestructive Assays Using Autoluminescent Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0028221.	1.4	9
2	Rufomycin Exhibits Dual Effects Against Mycobacterium abscessus Infection by Inducing Host Defense and Antimicrobial Activities. Frontiers in Microbiology, 2021, 12, 695024.	1.5	3
3	Rufomycins or Ilamycins: Naming Clarifications and Definitive Structural Assignments. Journal of Natural Products, 2021, 84, 2644-2663.	1.5	10
4	Antimycobacterial Rufomycin Analogues from Streptomyces atratus Strain MJM3502. Journal of Natural Products, 2020, 83, 657-667.	1.5	28
5	New tuberculosis drug targets, their inhibitors, and potential therapeutic impact. Translational Research, 2020, 220, 68-97.	2.2	97
6	Structure of the N-terminal domain of ClpC1 in complex with the antituberculosis natural product ecumicin reveals unique binding interactions. Acta Crystallographica Section D: Structural Biology, 2020, 76, 458-471.	1.1	23
7	Suadimins Aâ€“C, Unprecedented Dimeric Quinoline Alkaloids with Antimycobacterial Activity from Melodinus suaveolens. Organic Letters, 2019, 21, 7065-7068.	2.4	20
8	Strategies in anti-Mycobacterium tuberculosis drug discovery based on phenotypic screening. Journal of Antibiotics, 2019, 72, 719-728.	1.0	50
9	Antimicrobial Lavandulylated Flavonoids from a Sponge-Derived Streptomyces sp. G248 in East Vietnam Sea. Marine Drugs, 2019, 17, 529.	2.2	16
10	Rufomycin Targets ClpC1 Proteolysis in Mycobacterium tuberculosis and M. abscessus. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	68
11	High-Resolution Structure of ClpC1-Rufomycin and Ligand Binding Studies Provide a Framework to Design and Optimize Anti-Tuberculosis Leads. ACS Infectious Diseases, 2019, 5, 829-840.	1.8	40
12	Residual Complexity Does Impact Organic Chemistry and Drug Discovery: The Case of Rufomyazine and Rufomycin. Journal of Organic Chemistry, 2018, 83, 6664-6672.	1.7	24
13	Mutation in clpC1 encoding an ATP-dependent ATPase involved in protein degradation is associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerging Microbes and Infections, 2017, 6, 1-2.	3.0	41
14	QSAR-driven design, synthesis and discovery of potent chalcone derivatives with antitubercular activity. European Journal of Medicinal Chemistry, 2017, 137, 126-138.	2.6	96
15	Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity. Journal of Medicinal Chemistry, 2017, 60, 8647-8660.	2.9	43
16	Structural Sequencing of Oligopeptides Aided by ¹H Iterative Full-Spin Analysis. Journal of Natural Products, 2017, 80, 2630-2643.	1.5	9
17	Biophysical Screening of a Focused Library for the Discovery of CYP121 Inhibitors as Novel Antimycobacterials. ChemMedChem, 2017, 12, 1616-1626.	1.6	4
18	Discovery of an Interleukin 33 Inhibitor by Molecular Docking Simulation and <scp>NMR</scp> Analysis. Bulletin of the Korean Chemical Society, 2016, 37, 117-118.	1.0	3

#	Article	IF	Citations
19	Imidazo[1,2- a]Pyridine-3-Carboxamides Are Active Antimicrobial Agents against Mycobacterium avium Infection In Vivo. Antimicrobial Agents and Chemotherapy, 2016, 60, 5018-5022.	1.4	25
20	Design, syntheses, and anti-tuberculosis activities of conjugates of piperazino-1,3-benzothiazin-4-ones (pBTZs) with 2,7-dimethylimidazo [1,2-a]pyridine-3-carboxylic acids and 7-phenylacetyl cephalosporins. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2068-2071.	1.0	12
21	Antimycobacterial activity of pyrazinoate prodrugs in replicating and non-replicating Mycobacterium tuberculosis. Tuberculosis, 2016, 99, 11-16.	0.8	7
22	Arrival of Imidazo[2,1-b]thiazole-5-carboxamides: Potent Anti-tuberculosis Agents That Target QcrB. ACS Infectious Diseases, 2016, 2, 393-398.	1.8	64
23	Bioautography with TLC-MS/NMR for Rapid Discovery of Anti-tuberculosis Lead Compounds from Natural Sources. ACS Infectious Diseases, 2016, 2, 294-301.	1.8	43
24	Design, Syntheses, and Anti-TB Activity of 1,3-Benzothiazinone Azide and Click Chemistry Products Inspired by BTZ043. ACS Medicinal Chemistry Letters, 2016, 7, 266-270.	1.3	54
25	Syntheses and biological evaluations of highly functionalized hydroxamate containing and N-methylthio monobactams as anti-tuberculosis and Î²-lactamase inhibitory agents. MedChemComm, 2016, 7, 141-147.	3.5	12
26	Syntheses and evaluation of substituted aromatic hydroxamates and hydroxamic acids that target Mycobacterium tuberculosis. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4933-4936.	1.0	11
27	Trichormamides C and D, antiproliferative cyclic lipopeptides from the cultured freshwater cyanobacterium cf. Oscillatoria sp. UIC 10045. Bioorganic and Medicinal Chemistry, 2015, 23, 3153-3162.	1.4	22
28	Putting Tuberculosis (TB) To Rest: Transformation of the Sleep Aid, Ambien, and â€œAnagramsâ€•Generated Potent Antituberculosis Agents. ACS Infectious Diseases, 2015, 1, 85-90.	1.8	38
29	Diaza-anthracene Antibiotics from a Freshwater-Derived Actinomycete with Selective Antibacterial Activity toward Mycobacterium tuberculosis. ACS Infectious Diseases, 2015, 1, 168-174.	1.8	32
30	The Cyclic Peptide Ecumicin Targeting ClpC1 Is Active against Mycobacterium tuberculosis In Vivo. Antimicrobial Agents and Chemotherapy, 2015, 59, 880-889.	1.4	148
31	Syntheses and Antituberculosis Activity of 1,3-Benzothiazinone Sulfoxide and Sulfone Derived from BTZ043. ACS Medicinal Chemistry Letters, 2015, 6, 128-133.	1.3	45
32	Microplate Alamar Blue Assay (MABA) and Low Oxygen Recovery Assay (LORA) for Mycobacterium tuberculosis. Methods in Molecular Biology, 2015, 1285, 281-292.	0.4	84
33	Design and Syntheses of Anti-Tuberculosis Agents Inspired by BTZ043 Using a Scaffold Simplification Strategy. ACS Medicinal Chemistry Letters, 2014, 5, 587-591.	1.3	33
34	Design, synthesis and investigation on the structureâ€“activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents. European Journal of Medicinal Chemistry, 2014, 72, 26-34.	2.6	58
35	Discovery and Characterization of the Tuberculosis Drug Lead Ecumicin. Organic Letters, 2014, 16, 6044-6047.	2.4	50
36	Scaffold-switching: An exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3493-3498.	1.0	38

#	Article	IF	Citations
37	A novel combinatorial biocatalytic approach for producing antibacterial compounds effective against Mycobacterium tuberculosis (TB). Applied Microbiology and Biotechnology, 2013, 97, 7151-7163.	1.7	6
38	Identification of Novel Inhibitors of Nonreplicating Mycobacterium tuberculosis Using a Carbon Starvation Model. ACS Chemical Biology, 2013, 8, 2224-2234.	1.6	79
39	Chlorinated Coumarins from the Polypore Mushroom Fomitopsis officinalis and Their Activity against Mycobacterium tuberculosis. Journal of Natural Products, 2013, 76, 1916-1922.	1.5	38
40	Hytramycins V and I, Anti-Mycobacterium tuberculosisHexapeptides from aStreptomyces hygroscopicusStrain. Journal of Natural Products, 2013, 76, 2009-2018.	1.5	18
41	Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis, 2012, 92, 453-488.	0.8	193
42	Allylic thiocyanates as a new class of antitubercular agents. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6486-6489.	1.0	17
43	Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds. Bioorganic and Medicinal Chemistry, 2012, 20, 2214-2220.	1.4	96
44	Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity. ACS Medicinal Chemistry Letters, 2011, 2, 466-470.	1.3	161
45	NOC Chemistry for Tuberculosisâ€"Further Investigations on the Structureâ€"Activity Relationships of Antitubercular Isoxazoleâ€3â€carboxylic Acid Ester Derivatives. ChemMedChem, 2010, 5, 1667-1672.	1.6	11
46	Eucapsitrione, an Anti-Mycobacterium tuberculosis Anthraquinone Derivative from the Cultured Freshwater Cyanobacterium Eucapsis sp.. Journal of Natural Products, 2010, 73, 1441-1443.	1.5	31
47	Antiâ€TB polyynes from the roots of Angelica sinensis. Phytotherapy Research, 2008, 22, 878-882.	2.8	38
48	Library Synthesis Using 5,6,7,8-Tetrahydro-1,6-naphthyridines as Scaffolds. ACS Combinatorial Science, 2008, 10, 534-540.	3.3	24
49	A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. Journal of Antimicrobial Chemotherapy, 2008, 62, 1037-1045.	1.3	94
50	Efficacy of Quinoxaline-2-Carboxylate 1,4-Di- N -Oxide Derivatives in Experimental Tuberculosis. Antimicrobial Agents and Chemotherapy, 2008, 52, 3321-3326.	1.4	46
51	In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide. Journal of Antimicrobial Chemotherapy, 2008, 62, 547-554.	1.3	55
52	Low-Oxygen-Recovery Assay for High-Throughput Screening of Compounds against Nonreplicating Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2007, 51, 1380-1385.	1.4	286
53	ICAT-based comparative proteomic analysis of non-replicating persistent Mycobacterium tuberculosis. Tuberculosis, 2006, 86, 445-460.	0.8	52